We hope that this study can help clinicians and patients to choose the best scheme to improve the efficacy and safety of chemotherapy combined with different doses of IL-2 maintenance therapies for AML, and provide a better decision-making basis for clinical practice. The gene discussed is IL2; the disease is acute myeloid leukemia.